SH Stock Recent News

GUANGZHOU, China , July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive interim analysis results. Following this recommendation, Bio-Thera has decided to close patient enrollment ahead of schedule.

SH offers a 1x inverse daily performance of the S&P 500, making it suitable for hedging against short-term market volatility. SH is less prone to value decay than heavily leveraged inverse ETFs, allowing for longer holding periods, but is not ideal for long-term bearish bets. Geopolitical risks and upcoming trade policy deadlines could trigger market volatility, presenting tactical opportunities to use SH.

GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.

GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.

Key Points The SH and PSQ ETFs provide simple inverse exposure to major U.S. market indexes. For bearish-leaning risk takers, the SPXS ETF offers powerful leverage when the S&P 500 declines. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; get started by clicking here.(Sponsor) The first quarter of this year reminded optimistic investors that stocks don’t only go up. Trade war tensions, recession worries, and other factors could spur a market crash in 2025. Instead of using fancy strategies like short-selling stocks or buying put options, there’s an easier way that doesn’t require a margin account. Bearish-leaning investors can profit from a stock market crash of 20% or more by owning inverse exchange traded funds (ETFs). These funds are specifically designed to g

Inverse exchange-traded funds (ETFs) captivate certain investors with their promise of profiting from market declines, offering a hedge against downturns or a speculative bet on falling prices.

Inverse index ETFs like ProShares Short S&P 500 and ProShares Short Nasdaq-100 can effectively hedge portfolios during market downturns, enhancing long-term returns. Manual technical analysis and proprietary quantitative models can guide strategic use of inverse ETFs, providing protection and potential gains in volatile markets. In bull markets, consider inverse ETFs as short-term hedges. In bear markets, consider reversing the strategy to generate gains from inverse ETFs as long-term positions.

As economic concerns and trade tensions mount, strategists are lowering their outlooks for the S&P 500. A Q2 rebound is less likely for the index.

President Trump's tariffs unleash a fresh wave of chaos in global markets. Investors should keep an eye on these ETFs.

The S&P 500 has hit a new all-time high thanks to deregulation hopes in the Trump era, a resilient economy, easing inflation and an upbeat start to the earnings season.